|
gptkbp:instanceOf
|
gptkb:drug
histone deacetylase inhibitor
|
|
gptkbp:approvalYear
|
2006
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01XX50
|
|
gptkbp:bioavailability
|
43%
|
|
gptkbp:brand
|
gptkb:Zolinza
|
|
gptkbp:CASNumber
|
149647-78-9
|
|
gptkbp:category
|
antineoplastic agent
orphan drug
|
|
gptkbp:contraindication
|
pregnancy
severe hepatic impairment
|
|
gptkbp:developedBy
|
gptkb:Merck_&_Co.
|
|
gptkbp:eliminationHalfLife
|
2 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:firstSynthesized
|
1996
|
|
gptkbp:hasMolecularFormula
|
C14H20N2O3
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
vorinostat
|
|
gptkbp:indication
|
cutaneous manifestations of T-cell lymphoma
|
|
gptkbp:IUPACName
|
gptkb:N-hydroxy-N'-phenyloctanediamide
|
|
gptkbp:KEGGID
|
D06402
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits histone deacetylases
|
|
gptkbp:meltingPoint
|
174–175 °C
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
71%
|
|
gptkbp:PubChem_CID
|
gptkb:DB02546
gptkb:CHEMBL1161
5311
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
anorexia
fatigue
thrombocytopenia
|
|
gptkbp:structure
|
hydroxamic acid derivative
|
|
gptkbp:studiedBy
|
investigated in HIV latency reversal
investigated in other cancers
|
|
gptkbp:synonym
|
gptkb:SAHA
gptkb:suberoylanilide_hydroxamic_acid
|
|
gptkbp:target
|
gptkb:HDAC2
gptkb:HDAC3
gptkb:HDAC6
gptkb:HDAC1
|
|
gptkbp:UNII
|
6QJ7C90B1H
|
|
gptkbp:usedFor
|
treatment of cutaneous T-cell lymphoma
|
|
gptkbp:bfsParent
|
gptkb:Zolinza
|
|
gptkbp:bfsLayer
|
5
|